Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Brandt

Cardiovascular Disease Santa Cruz, CA Medical Doctor

NPI 1518946664 CMS profile 341565

2025 Soquel Ave, Santa Cruz, CA 95062

Open in the dashboard

General payments

$22,011

284 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Brandt of Santa Cruz, CA is reported in the CMS Open Payments database as having received $22,011 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,811 37
2024 General $7,459 14
2023 General $4,359 50
2022 General $380 4
2021 General $451 6
2020 General $182 3
2019 General $5,369 170

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Brandt
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ryan Brandt were reported at $3,811. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ryan Brandt Cardiovascular Disease median Middle half National median
2019 $5,369 $450 $127–$1,392 $163
2020 $182 $242 $77–$751 $114
2021 $451 $335 $101–$1,037 $132
2022 $380 $395 $121–$1,211 $149
2023 $4,359 $443 $136–$1,283 $160
2024 $7,459 $450 $136–$1,323 $164
2025 $3,811 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $6,889 4 payments
  2. Medtronic, Inc. $5,618 69 payments
  3. Medtronic Vascular, Inc. $4,188 160 payments
  4. Philips Electronics North America Corporation $1,199 7 payments
  5. Biotronik Inc. $1,191 12 payments
  6. Abbott Laboratories $762 11 payments
  7. Penumbra, Inc. $717 3 payments
  8. CVRx, Inc. $549 6 payments
  9. HeartFlow, Inc. $279 3 payments
  10. Baxter Healthcare $197 3 payments
  11. Other $422 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,364 252 payments
  2. Travel and Lodging $7,048 31 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $6,600 1 payment
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $6,889 4 payments
  2. Reveal LINQ $1,954 23 payments
  3. EVERA MRI XT DR SURESCAN $1,137 7 payments
  4. Micra Pacemakers $973 9 payments
  5. MICRA Pacemakers $862 25 payments
  6. Indigo $717 3 payments
  7. LINQ II $628 9 payments
  8. SelectSecure $576 4 payments
  9. Barostim Neo System $549 6 payments
  10. Coronary Undivided $505 3 payments
  11. Other $5,745 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

8,841

Median for Interventional Cardiology: 2,236

Drug cost

$2,729,014

Median for Interventional Cardiology: $380,412

Branded share of claims

34.4%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,263 $1,504,590
Entresto Sacubitril/Valsartan Brand 461 $556,902
Xarelto Rivaroxaban Brand 186 $200,238
Jardiance Empagliflozin Brand 158 $171,348
Repatha Sureclick Evolocumab Brand 76 $74,104
Praluent Pen Alirocumab Brand 54 $50,962
Metoprolol Succinate Generic 1,125 $21,842
Farxiga Dapagliflozin Propanediol Brand 26 $17,302
Nexletol Bempedoic Acid Brand 23 $12,067
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 255 $11,537

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$664,090

Of which drugs: $2,348

Medicare patients

3,016

Average age 77

Services billed

16,135

1,528 women, 1,488 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 45%
Atrial fibrillation 34%
Ischemic heart disease 33%
Diabetes 24%
Chronic kidney disease 24%
Heart failure 22%
Depression 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) J0153 Office 82 5,668 $2,038
Injection, dobutamine hydrochloride, per 250 mg J1250 Office 40 40 $271

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record